Genetic markers of enhanced functional antibody responses to COVID-19 vaccination
- Author(s)
- Purcell, RA; Aurelia, LC; Allen, LF; Bond, KA; Williamson, DA; Trevillyan, JM; Trubiano, JA; Wines, BD; Hogarth, PM; Juno, JA; Wheatley, AK; Nguyen, THO; Subbarao, K; Kedzierska, K; Kent, SJ; Mahanty, S; Selva, KJ; Chung, AW;
- Journal Title
- Vaccine
- Publication Type
- Research article
- Abstract
- INTRODUCTION: Substantial population-level variation in vaccine-specific antibody responses has been observed following global coronavirus disease 2019 (COVID-19) vaccination efforts. Beyond the influence of clinical and demographic features, immunogenetic variation is suggested to underlie divergent serological responses following COVID-19 vaccination of distinct populations. METHODS: Immunoglobulin G1 (IgG1) allotypic markers (G1m) for 121 COVID-19 vaccinated healthy adults were genotyped via Sanger sequencing. Vaccine-specific IgG and Fc gamma receptor (FcγR) engagement were characterised via bead-based multiplex array. RESULTS: Following two COVID-19 vaccine doses, G1m1,17(+/+) compared to G1m-1,3(+/+) vaccinees had increased IgG and FcγR engagement specific for the antigenically conserved SARS-CoV-2 Spike 2 (S2) domain. IgG targeting antigenically novel SARS-CoV-2 receptor binding domain (RBD) trended higher in G1m1,17(+/+) vaccinees, facilitating increased RBD-specific FcγR2a-R131 and FcγR2b binding. CONCLUSION: Primary COVID-19 vaccination induced increased S2-specific IgG in G1m1,17(+/+) vaccinees, facilitating enhanced anti-viral FcγR engagement and suggesting immunogenetics may be a valuble consideration for next-generation vaccine design.
- Keywords
- Fc functions; FcγR polymorphism; IgG Allotype; Immunogenetics; SARS-CoV-2; Vaccine
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1016/j.vaccine.2025.127379
- Open Access at Publisher's Site
https://doi.org/10.1016/j.vaccine.2025.127379- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-08-08 07:40:11
Last Modified: 2025-08-08 07:42:02